ClearNote Health: Series DDevelops noninvasive blood-based early detection tests for pancreatic and ovarian cancersOct 4, 2026RoundOSClearNote HealthCompany profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedAIBiotechUnited StatesHealthtechNorth AmericaSeries C+